Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells

Nishimura, Goshi; Yanoma, Shunsuke; Mizuno, Hideo; Satake, Kenichi; Taguchi, Takahide; Ikeda, Yoichi; Tsukuda, Mamoru

doi:10.1016/s0304-3835(00)00495-x

Cited by 17 publications

(19 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10) S-1 administration provides prolonged high concentrations of 5-FU in tumor tissue, having a superior inhibitory effect on tumor growth. In our previous study, 3) the minimum 5-FU concentration in the tumor for significant tumor growth suppression was 300 ng/g. In this study, we administered S-1 at 5 mg/kg, which did not afford significant tumor growth The effect of administration of combinations of two among these three drugs, which have different mechanisms of action, was investigated in tumor-bearing nude mice.…”

Section: Discussionmentioning

confidence: 87%

“…In vivo tumor growth assay To evaluate the addictive effects of tiracoxib, probucol and S-1 on tumor growth inhibition, each drug was used at a not significantly effective dosage, based on our previous data. [1][2][3] KB cells (5×10 6 ) were injected subcutaneously into the left flanks of mice. The tumor size was measured once a week by determining two perpendicular dimensions with calipers, and the volume in mm 3 was calculated from the formula (a×b 2 )/2, where a is the longer and b is the smaller dimension.…”

Section: Methodsmentioning

confidence: 99%

“…However, it is impossible to be sure that there are no remnant tumor cells in the entire locoregional field. We have already reported inhibitory effects of tiracoxib, 1) probucol 2) and S-1 3) on tumor growth. According to the concept of tumor dormancy therapy, which aims to prolong the life of patients with cancer, these drugs might be efficacious for maintenance therapy to reduce the tumor-relapse rate.…”

mentioning

confidence: 96%

See 2 more Smart Citations

An Experimental Model of Tumor Dormancy Therapy for Advanced Head and Neck Carcinoma

Nishimura

Yanoma

Satake

et al. 2000

Japanese Journal of Cancer Research

Self Cite

View full text Add to dashboard Cite

An experimental model of tumor dormancy therapy for advanced head and neck carcinoma was developed. After transplantation of KB cells into nude mice, the mice were given tiracoxib, a selective cyclooxygenase (COX)-2 inhibitor, probucol, an antioxidant, and S-1, an oral pro-drug of 5-fluorouracil (5-FU), or combinations of two of them. The combined administration of tiracoxib with probucol significantly inhibited the tumor growth. The angiogenesis in this group was markedly reduced. Tiracoxib and probucol did not affect the intratumoral concentration of 5-FU when coadministered with S-1. The combined use of tiracoxib and probucol is thus a candidate for use in maintenance therapy after the primary therapy for patients with advanced head and neck carcinoma.

show abstract

Section: Discussionmentioning

confidence: 87%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 96%

See 1 more Smart Citation

An Experimental Model of Tumor Dormancy Therapy for Advanced Head and Neck Carcinoma

Nishimura

Yanoma

Satake

et al. 2000

Japanese Journal of Cancer Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6] In a late phase II clinical trial involving patients with head and neck cancer, the overall success rate for oral cavity lesions was 36.4%; for those with a primary focus, it was 46.9%, while for those with metastasis to neck lymph nodes, it was 21.7%. This rate was high compared to other anti-cancer agents.…”

Section: Introductionmentioning

confidence: 99%

Two elderly patients with advanced maxillary gingival carcinoma with complete response to concurrent radiotherapy and S-1 chemotherapy

Yoshizawa

Nozaki

Yoshida

et al. 2010

Asian Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

Abbreviations: OSCC, oral squamous cell carcinoma; CR, complete response; BSA, body 2 surface area; RECIST, response evaluation criteria in solid tumors; CTCAE v3.0, common terminology criteria for Adverse Events version 3.0; ADL, activities of daily living.3 Abstract: The use of the novel oral fluoropyrimidine anticancer drug S-1 as a single-agent or in combined chemotherapy has been reported to be useful for the treatment of advanced oral cancer.We report two elderly patients with advanced oral cancer who achieved complete response (CR) after concurrent radiotherapy and S-1 chemotherapy. Patient 1 was an 81-year-old woman who had a 50 × 40 mm tumor erosion in the right upper gingival region. At 2.5 years after the end of concurrent radiotherapy and S-1 chemotherapy, tumor relapse was observed, although CR continued temporarily. The patient died 3 years after the end of concurrent radiotherapy and S-1 chemotherapy due to tumor relapse and high blood pressure resulting in deterioration of patient condition. Patient 2 was an 89-year-old woman who had a 40 × 30 mm tumor ulcer in the right gingiva. Neither relapse nor metastasis was seen, and patient condition remained good for the 3 years after concurrent radiotherapy and S-1 chemotherapy. In both patients, MRI showed that the tumor had deeply invaded the palatal bone, almost reaching the nasal cavity, with metastasis 4 to the right upper superior internal jugular nodes. In both patients, biopsy showed a well-differentiated squamous cell carcinoma. Concurrent radiotherapy and S-1 chemotherapy induced CR without severe adverse effects.

show abstract

“…7,8 S-1 has shown promising results for the treatment of a variety of solid cancers, including head and neck cancer. [9][10][11][12][13] Moreover, owing to its oral administration, S-1 has been considered a suitable agent in the outpatient setting, which is attractive for patient convenience. Its ease of administration and reduced hospitalization times can be benefi cial in palliative treatment.…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer

Suzuki

Ishikawa

2009

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells

Cited by 17 publications

References 8 publications

An Experimental Model of Tumor Dormancy Therapy for Advanced Head and Neck Carcinoma

An Experimental Model of Tumor Dormancy Therapy for Advanced Head and Neck Carcinoma

Two elderly patients with advanced maxillary gingival carcinoma with complete response to concurrent radiotherapy and S-1 chemotherapy

Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer

Contact Info

Product

Resources

About